KYORIN and Cyrano Therapeutics Enter into an Option Agreement for CYR-064 for the Treatment of Post-Viral Loss of Smell in Japan

Whats Happening:

Cyrano Therapeutics has entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. for CYR-064, a novel treatment for post-viral loss of smell. KYORIN will pay an option fee and, if exercised, provide Cyrano with upfront payment, milestone payments, and royalties based on net sales in Japan.

Key Moves:

• Cyrano Therapeutics and KYORIN enter option agreement for CYR-064 in Japan

• KYORIN to pay option fee, with potential for upfront, milestone, and royalty payments

• CYR-064 currently in Phase 2 clinical trial in the United States

By The Numbers:

• 40% of patients with olfactory dysfunction experience more than two safety events

• 43% of patients with olfactory dysfunction experience depression

• CYR-064 Phase 2 trial data expected in second half of 2025

Bottom Line:

The option agreement between Cyrano Therapeutics and KYORIN for CYR-064 represents a significant step in addressing post-viral loss of smell, a condition with no current FDA-approved therapy. This collaboration could lead to the development and commercialization of a novel treatment in Japan, potentially improving the quality of life for many patients suffering from this sensory impairment.

Read Full Article